NASDAQ:CBIO
Delisted
Catalyst Biosciences Stock News
$0.511
+0 (+0%)
At Close: Dec 14, 2023
Why Is Catalyst Biosciences (CBIO) Stock Up 55% Today?
08:00am, Tuesday, 28'th Feb 2023
Catalyst Biosciences (NASDAQ: CBIO ) stock is rocketing higher on Tuesday after the company announced an asset purchase agreement with GC Biopharma. That agreement has Catalyst Biosciences selling thr
Catalyst Biosciences: Shareholders Should Reap Benefits From Owning The Stock
12:23pm, Monday, 15'th Aug 2022
Catalyst Biosciences is highly committed to its cash distribution plan to shareholders of up to $65 million in the near future, with only a $58 million market capitalization. If the proxy contest is c
Has Catalyst Biosciences (CBIO) Outpaced Other Medical Stocks This Year?
10:50am, Tuesday, 28'th Jun 2022
Here is how Catalyst Biosciences, Inc. (CBIO) and Humana (HUM) have performed compared to their sector so far this year.
5 Penny Stocks To Watch With High Short Interest, Are They A Buy Now?
11:03am, Friday, 17'th Jun 2022
Penny stocks are red hot right now if you know where to… The post 5 Penny Stocks To Watch With High Short Interest, Are They A Buy Now? appeared first on Penny Stocks to Buy, Picks, News and Informa
Hot Penny Stocks to Buy This Week? 3 to Watch
08:21pm, Wednesday, 25'th May 2022
Which penny stocks are you watching right now? The post Hot Penny Stocks to Buy This Week?
Penny Stocks To Buy Now? 3 With Unusual Options Activity To Watch
12:30pm, Tuesday, 24'th May 2022
Penny stocks with unusual options activity today. The post Penny Stocks To Buy Now?
Why Is Catalyst Biosciences (CBIO) Stock Soaring 170% Today?
10:36am, Monday, 23'rd May 2022
Catalyst Biosciences (CBIO) stock is rocketing higher on Monday after announcing the sale of its protease medicines portfolio. The post Why Is Catalyst Biosciences (CBIO) Stock Soaring 170% Today?
Why Catalyst Biosciences Shares Are Skyrocketing Today
10:01am, Monday, 23'rd May 2022
Catalyst Biosciences Inc (NASDAQ: CBIO) shares are trading higher by 180.26% at $1.06 after the company announced it sold its complement portfolio for $60 million. A definitive asset purchase and sale
Catalyst Biosciences Stock More Than Doubles After Assets Sale To Vertex
10:01am, Monday, 23'rd May 2022
Catalyst Biosciences Inc (NASDAQ: CBIO) has agreed to sell its portfolio of protease medicines that regulate complement to Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) for $60 million. "Thi
Penny Stocks To Buy Now? 4 To Watch Under $1
09:34am, Monday, 23'rd May 2022
Penny stocks under $1 to watch right now. The post Penny Stocks To Buy Now?
Biogen ends partnership with Catalyst Biosciences for eye disease candidate
03:52pm, Wednesday, 16'th Mar 2022 Seeking Alpha
Biogen (BIIB) and Catalyst Biosciences (CBIO) have ended their collaboration on potential treatments for dry AMD (dAMD), a leading cause of blindness.Per the terms of the agreement,…
Catalyst Biosciences Regains Rights to CB 2782-PEG for the Treatment of Dry AMD Expands CBIO''s Complement Portfolio in Ophthalmology
09:00pm, Tuesday, 15'th Mar 2022 Benzinga
SOUTH SAN FRANCISCO, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO ) today announced that the company has regained full rights to CB 2782-PEG, a C3-degrader for the treatment of dry AMD (dAMD). Under the terms of the agreement, Biogen has returned the rights for further development on CB 2782-PEG and has ended the collaboration on other potential AMD treatments. "We are delighted to regain the rights to CB 2782-PEG which unlocks the full potential of our complement proteases in ophthalmology. We now have two wholly-owned, potentially best-in-class development candidates, CB 2782-PEG and CB 4332, a long half-life complement factor I fusion, each targeting clinically validated mechanisms in dry AMD. Dry AMD, a leading cause of blindness in its severe form for which there are no currently approved drugs, represents a significant market opportunity, estimated at over $10B," said Nassim Usman, Ph.D., chief executive officer of Catalyst Biosciences. About Catalyst Biosciences, the Protease Medicines …
U.S. Xpress Enterprises And 4 Other Penny Stocks Bought By Insiders
11:50am, Thursday, 17'th Feb 2022 Benzinga
Although US crude futures fell over 2% on Thursday, there were a few notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company''s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga''s insider transactions platform. Catalyst Biosciences The Trade: Catalyst Biosciences, Inc. (NASDAQ: CBIO ) Chief Scientific Officer Grant E Blouse acquired a total of 3,250 shares at an average price of $0.46. To acquire these shares, it cost $1.5 thousand. What’s Happening: Catalyst Biosciences, last month, received rare pediatric disease designation for CB 4332 for the treatment of CFI deficiency. What Catalyst Biosciences Does: Catalyst Biosciences Inc is a clinical-stage biopharmaceutical company. It mainly focuses on developing novel medicines to address serious medical conditions …
Catalyst Biosciences Inc. (NASDAQ: CBIO): Can A Stock Be -38.80% Lower Year-To-Date And Still Be A Loser?
04:00pm, Friday, 11'th Feb 2022 Marketing Sentinel
Catalyst Biosciences Inc. (NASDAQ:CBIO)s traded shares stood at 1.0 million during the last session, with the companys beta value hitting 2.01. At the close of trading, the stocks price was $0.56, to imply an increase of 1.21% or $0.01 in intraday trading. The CBIO shares 52-week high remains $7.55, putting it -1248.21% down since that Catalyst Biosciences Inc. (NASDAQ: CBIO): Can A Stock Be -38.80% Lower Year-To-Date And Still Be A Loser? Read More »
Dry Age-related Macular Degeneration Pipeline Landscape Analysis by DelveInsight
06:00pm, Thursday, 10'th Feb 2022 Benzinga
New York, USA, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Dry Age-related Macular Degeneration Pipeline Landscape Analysis by DelveInsight For patients with advanced Dry A ge-Related Macular Degeneration, also called geographic atrophy (GA), there is currently no FDA-approved therapy. There are, however, several treatments that are currently in clinical trials. Apl-2, Zimura, Oracea, and others are the drug molecules recently being investigated for the treatment of late-stage dry AMD. Strong Dry Age-related Macular Degeneration pipeline is anticipated to augment the market. DelveInsight''s '' Dry Age-related Macular Degeneration Pipeline Insight 2021 '' report provides comprehensive global coverage of available, marketed, and pipeline Dry AMD therapies in various stages of clinical development, major pharmaceutical players working to advance the pipeline space and future growth potential of the Dry Age-related Macular Degeneration pipeline domain. Key Takeaways from the Dry Age-related Macular Degeneration Pipeline Report DelveInsight''s Dry Age-related Macular Degeneration Pipeline analysis depicts a robust space with 45+ active players working to develop 45+ pipeline therapies.